{
  "pmcid": "8923580",
  "sha256": "da16592cf2b6380c329d3145b98bc6e33b91841d4f51860036bce3ee28eacd13",
  "timestamp_utc": "2025-11-09T16:19:48.598346+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.751818181818184,
    "reading_ease": 45.96629870129871,
    "word_count": 770
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "In this randomized trial, we compared the results of US-guided steroid injections targeting both subcompartments and the EPB subcompartment alone in patients with de Quervain disease."
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "A randomized controlled study was performed at a single center between August 2018 and March 2021."
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients with a diagnosis of de Quervain disease and with a complete intracompartmental septum between the APL and the EPB tendons were included."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients were randomly assigned to US-guided injections targeting both subcompartments (n = 25) or the EPB subcompartment alone (n = 25)."
      },
      "Objective": {
        "score": 1,
        "evidence": "Do patients who receive a steroid injection in the EPB subcompartment alone have lower pain scores at 6 weeks and at 3 months after US-guided injection compared with patients who receive an injection in both subcompartments?"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "To determine statistical power, the VAS score for pain at 6 weeks after the injection was used as the primary outcome variable."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Patients were randomly assigned to US-guided injections targeting both subcompartments (n = 25) or the EPB subcompartment alone (n = 25)."
      },
      "Blinding": {
        "score": 2,
        "evidence": "Pre- and postinjection clinical outcome assessments were completed by orthopaedic surgery residents not involved in patient management."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Patients were randomly assigned to US-guided injections targeting both subcompartments (n = 25) or the EPB subcompartment alone (n = 25)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Four percent (n = 2, 1 in each group) of patients were excluded after randomization because their pain level was not registered."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "There were no differences in the VAS scores between the both-subcompartment group and the EPB group at 6 weeks (10 ± 6 versus 10 ± 7, mean difference -0.08 [95% CI -4.08 to 3.91]; p = 0.97)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events related to treatment (such as tendon rupture, infections, and numbness) occurred in either group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}